Website Video

Partner of choice in specialty, hospital, and rare disease medicines

Learn More

ADVANZ PHARMA is a global pharmaceutical company with the purpose to improve patients’ lives by providing the specialty, hospital, and rare disease medicines they depend on.

Our ambition is to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with innovative biopharma and pharmaceutical development companies to bring medicines to patients.

Headquartered in London, UK, we have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia.

Our Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialisation partner network complement our global operations.

ADVANZ PHARMA’s product portfolio and pipeline comprises innovative medicines, specialty generics & biosimilars, and originator brands. Our products and pipeline cover a broad range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, CNS, and, more broadly, rare diseases.

We can only achieve our ambition with the passion of our dedicated and highly qualified people, acting in line with our company values of entrepreneurship, speed, and integrity.

Latest News —

Image for ADVANZ PHARMA signs an exclusive agreement with  GP Pharm for a peptide specialty injectable generic for multiple European countries

Press Releases — 04 Sep 2023

ADVANZ PHARMA signs an exclusive agreement with GP Pharm for a peptide specialty injectable generic for multiple European countries

Learn more
Image for ADVANZ PHARMA Releases Environmental, Social & Governance (ESG) Report for 2022-2023

Press Releases — 01 Sep 2023

ADVANZ PHARMA Releases Environmental, Social & Governance (ESG) Report for 2022-2023

Learn more
Image for Alvotech and Advanz Pharma extend strategic partnership  to commercialize five proposed biosimilars in Europe

Press Releases — 24 May 2023

Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe

Learn more
Image for ADVANZ PHARMA launches Palmeux®/Paliperidone 1-month long-acting injection across various European countries

Press Releases — 17 Feb 2023

ADVANZ PHARMA launches Palmeux®/Paliperidone 1-month long-acting injection across various European countries

Learn more
Image for ADVANZ PHARMA enters into an exclusive agreement with Alvotech to commercialise a proposed biosimilar to Xolair® (omalizumab)

Press Releases — 06 Feb 2023

ADVANZ PHARMA enters into an exclusive agreement with Alvotech to commercialise a proposed biosimilar to Xolair® (omalizumab)

Learn more
Image for ADVANZ PHARMA to receive exclusive rights from Applied Therapeutics to commercialise AT-007 (govorestat) in Europe

Press Releases — 04 Jan 2023

ADVANZ PHARMA to receive exclusive rights from Applied Therapeutics to commercialise AT-007 (govorestat) in Europe

Learn more

Our portfolio —

ADVANZ PHARMA’s product portfolio and pipeline comprises innovative medicines, specialty generics & biosimilars, and originator brands

Our products cover a broad range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare diseases.

Careers & Culture —

The success of any company is driven by its people, and we are no different. We aim to be the best team in the industry by embracing challenges and change. We live our company values Entrepreneurship, Speed, and Integrity.

Our Partnerships —

Partnerships are a fundamental part of our business.. We work with >300 partners in production, development, portfolio licensing, and commercialization. We cooperate very closely with them and invest significantly to help broaden patient access and to improve health outcomes.